Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more